Enasidenib is a small molecule inhibiting mutant IDH2, which is overexpressed in hematological cancers: it has high selectivity, good solubility and oral bioavailability [33]. This evidence concerns the gene IDH2 and hematopoietic and lymphoid cell neoplasm.